Gene · 151306
Papers2,833
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,833
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| FXR in bone metabolism: An emerging regulator. | iScience | 2026 | 41732262 | PubTator, text mining | PubMed |
| Cross-sectional association between gallstone disease and nonalcoholic fatty liver disease: Exploring the mediating roles of hematological and biochemical markers. | Medicine (Baltimore) | 2026 | 41731811 | PubTator, text mining | PubMed |
| BMI-stratified phenotypes of polycystic ovary syndrome: advances in gut microbiota research and personalized management strategies. | Front Endocrinol (Lausanne) | 2026 | 41727680 | PubTator, text mining | PubMed |
| Pleiotropic immunoregulation by bile acids in pathophysiology. | Front Immunol | 2026 | 41727485 | PubTator, text mining | PubMed |
| Aging-Driven Inter-Organ Crosstalk in Postmenopausal Osteoporosis: From Immunometabolic Drift to Multisystem Frailty. | FASEB J | 2026 | 41721711 | PubTator, text mining | PubMed |
| Pediatric Cholestatic Diseases in the Era of Ileal Bile Acid Transporter (IBAT) Inhibitors. | Pediatr Rep | 2026 | 41718432 | PubTator, text mining | PubMed |
| Integrating bile acid metabolism into precision nutrition strategies for improved swine performance. | Anim Nutr | 2026 | 41716838 | PubTator, text mining | PubMed |
| Pathogenesis and intervention strategies for metabolic dysfunction-associated fatty liver disease from the perspective of the gut-microbiota-liver axis. | Front Immunol | 2026 | 41716420 | PubTator, text mining | PubMed |
| Exploring osteosarcopenia from the gut microbiota perspective: mechanistic insights and therapeutic potentials based on the gut-muscle-bone Axis. | Front Microbiol | 2026 | 41716280 | PubTator, text mining | PubMed |
| Interactions of bile acids and gut microbiota modulate neurological health: a comprehensive review on mechanisms and therapeutic potential of dietary phytochemicals. | Front Microbiol | 2026 | 41716273 | PubTator, text mining | PubMed |
| Lipids in kidney diseases: from systemic imbalance to intrarenal alterations of cellular lipid metabolism in rare and common kidney diseases. | J Mol Med (Berl) | 2026 | 41714434 | PubTator, text mining | PubMed |
| Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system. | Diabetes Obes Metab | 2026 | 41705640 | PubTator, text mining | PubMed |
| Emerging mechanisms of microplastic-induced skin diseases: a perspective from the gut-skin axis. | J Transl Med | 2026 | 41699656 | PubTator, text mining | PubMed |
| Lipid metabolism in homeostasis and disease. | Signal Transduct Target Ther | 2026 | 41692800 | PubTator, text mining | PubMed |
| The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors. | Biochem Pharmacol | 2026 | 41692350 | PubTator, text mining | PubMed |
| Correction to "Identification of a Crosstalk Among TGR5, GLIS2, and TP53 Signaling Pathways in the Control of Undifferentiated Germ Cell Homeostasis and Chemoresistance". | Adv Sci (Weinh) | 2026 | 41677345 | PubTator, text mining | PubMed |
| Bile acid profiles reflect metabolic adaptability to rapid weight loss in boxers. | BMC Sports Sci Med Rehabil | 2026 | 41664082 | PubTator, text mining | PubMed |
| Modulating the Gut Microbiome as a Therapeutic Approach in Multiple Sclerosis: Implications for Gut-Brain Interactions and Immune Pathways: A Narrative Review. | Brain Behav | 2026 | 41645047 | PubTator, text mining | PubMed |
| Metabolomic insights into associations between adiposity markers and liver cancer risk: Results from a prospective cohort study and Mendelian randomization analysis. | PLoS Med | 2026 | 41628182 | PubTator, text mining | PubMed |
| Non-invasive liquid biopsy based on metabolomic profiling improves diagnosis and early warning of severe acute pancreatitis. | NPJ Digit Med | 2026 | 41611815 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/151306/papers?page=9